Heterocyclic PD-1/PD-L1 Modulators for Restoring T Cell Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells evade the immune system by altering the expression of co-stimulatory and co-inhibitory molecules, particularly through the PD-1/PD-L1 protein interaction, necessitating the development of compounds that can block this interaction to enhance T cell response.
Innovation Solution
Development of heterocyclic compounds that modulate PD-1/PD-L1 protein interaction, specifically represented by Formula (I) and its pharmaceutically acceptable salts or stereoisomers, which are administered to inhibit this interaction and potentially treat diseases like cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cancer cells alter expression of co-inhibitory molecules like PD-L1, then they can evade immune system detection and suppression, but this creates an opportunity to block the PD-1/PD-L1 interaction to restore T cell response
Solution Approach 1:
The patent employs small molecule compounds as intermediaries that bind to PD-1 receptor, preventing the direct interaction between PD-1 and PD-L1. These compounds act as mediators that disrupt the inhibitory signaling pathway, thereby restoring T cell function without directly modifying the cancer cells or immune cells themselves.
Solution Approach 2:
The invention changes the binding parameters of the PD-1/PD-L1 interaction by introducing compounds that alter the affinity and specificity of the protein-protein interaction. By modifying the binding characteristics through small molecule intervention, the patent restores immune recognition and response against cancer cells.
2Stability of the object's composition
If PD-1 signaling is activated to prevent autoimmunity and promote self-tolerance, then immune homeostasis is maintained, but this same mechanism allows cancer cells to suppress T cell response
Solution Approach 1:
The patent applies local quality modification by selectively interfering with PD-1 signaling in the context of cancer immunity while preserving overall immune homeostasis. The small molecule compounds specifically target the pathological PD-1/PD-L1 interaction in tumor microenvironments without disrupting the physiological negative feedback mechanisms that prevent autoimmunity.
Solution Approach 2:
The invention implements partial action by selectively blocking PD-1 signaling only in contexts where it contributes to cancer immune evasion, rather than completely abolishing PD-1 function. This partial intervention restores anti-tumor immunity while maintaining the protective self-tolerance functions of PD-1 signaling.
Data Source
AI summary
Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.